Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer

被引:44
作者
Jung, Se Jin [1 ]
Woo, Sang Myung [1 ]
Park, Hyung Ki [1 ]
Lee, Woo Jin [1 ]
Han, Mi Ah [2 ,3 ]
Han, Sung-Sik [1 ]
Kim, Seong Hoon [1 ]
Park, Sang-Jae [1 ]
Kim, Tae Hyun [1 ]
Koh, Young Hwan [1 ]
Hong, Eun Kyung [1 ]
机构
[1] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[2] Natl Canc Ctr, Natl Canc Control Inst, Goyang Si 410769, Gyeonggi Do, South Korea
[3] Chosun Univ, Coll Med, Dept Prevent Med, Kwangju, South Korea
关键词
Adjuvant therapy; Biliary tract cancer; Recurrence; LYMPH-NODE ASSESSMENT; INTRAHEPATIC CHOLANGIOCARCINOMA; BILE-DUCT; POSTOPERATIVE RADIOTHERAPY; HILAR CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; ADJUVANT; SURVIVAL; ADENOCARCINOMA; CHEMORADIATION;
D O I
10.1159/000339695
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives:This study aimed to provide further insights into the indications for adjuvant therapeutic strategies via analysis of the sites of initial recurrence after resection of gallbladder cancer (GBC) and intrahepatic (IHC) and extrahepatic cholangiocarcinoma (EHC). Methods: Patients with biliary tract cancer who underwent potentially curative resection were identified from the database. Sites of initial disease recurrence were categorized as locoregional or distant. Results: Between March 2001 and April 2009, 231 patients underwent curative resection. Initial GBC and IHC recurrence involving a distant site occurred in 70.8 and 86.8% patients, respectively, compared to 56.9% patients with EHC (p = 0.002). The median time to disease recurrence (TTR) was shorter among the GBC and IHC groups compared with that in EHC patients (6.3 and 6.7 vs. 13.1 months, respectively; p = 0.003). Moreover, median times to distant recurrence in GBC and IHC groups were shorter than that in EHC (5.8 and 6.5 vs. 14.1 months, respectively; p = 0.002). Conclusions: After resection, recurrent GBC and IHC are more likely to involve a distant site and are associated with significantly shorter TTR than recurrent EHC. These findings suggest that an adjuvant therapeutic strategy targeting distant disease is likely to have a significant impact on the overall management of GBC and IHC. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:83 / 90
页数:8
相关论文
共 31 条
  • [1] Adjuvant therapy for resected extrahepatic cholangiocarcinoma: A review of the literature and future directions
    Anderson, Carryn
    Kim, Richard
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (04) : 322 - 327
  • [2] Prognostic molecular markers in cholangiocarcinoma: A systematic review
    Briggs, Christopher D.
    Neal, Christopher P.
    Mann, Christopher D.
    Steward, William P.
    Manson, Margaret M.
    Berry, David P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (01) : 33 - 47
  • [3] Radiotherapy and Chemotherapy as Therapeutic Strategies in Extrahepatic Biliary Duct Carcinoma
    Brunner, Thomas B.
    Eccles, Cynthia L.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (12) : 672 - 680
  • [4] Medical progress - Biliary tract cancers
    de Groen, PC
    Gores, GJ
    LaRusso, NF
    Gunderson, LL
    Nagorney, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) : 1368 - 1378
  • [5] Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment
    de Jong, Mechteld C.
    Nathan, Hari
    Sotiropoulos, Georgios C.
    Paul, Andreas
    Alexandrescu, Sorin
    Marques, Hugo
    Pulitano, Carlo
    Barroso, Eduardo
    Clary, Bryan M.
    Aldrighetti, Luca
    Ferrone, Cristina R.
    Zhu, Andrew X.
    Bauer, Todd W.
    Walters, Dustin M.
    Gamblin, T. Clark
    Nguyen, Kevin T.
    Turley, Ryan
    Popescu, Irinel
    Hubert, Catherine
    Meyer, Stephanie
    Schulick, Richard D.
    Choti, Michael A.
    Gigot, Jean-Francois
    Mentha, Gilles
    Pawlik, Timothy M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) : 3140 - 3145
  • [6] NATURAL-HISTORY OF UNRESECTED CHOLANGIOCARCINOMA - PATIENT OUTCOME AFTER NONCURATIVE INTERVENTION
    FARLEY, DR
    WEAVER, AL
    NAGORNEY, DM
    [J]. MAYO CLINIC PROCEEDINGS, 1995, 70 (05) : 425 - 429
  • [7] CHOLANGIOCARCINOMA - CURRENT TREATMENT OPTIONS
    Friman, S.
    [J]. SCANDINAVIAN JOURNAL OF SURGERY, 2011, 100 (01) : 30 - 34
  • [8] Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
    Hughes, Michael A.
    Frassica, Deborah A.
    Yeo, Charles J.
    Riall, Taylor S.
    Lillemoe, Keith D.
    Cameron, John L.
    Donehower, Ross C.
    Laheru, Daniel A.
    Hruban, Ralph H.
    Abrams, Ross A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (01): : 178 - 182
  • [9] Adequate Lymph Node Assessment for Extrahepatic Bile Duct Adenocarcinoma
    Ito, Kaori
    Ito, Hiromichi
    Allen, Peter J.
    Gonen, Mithat
    Klimstra, David
    D'Angelica, Michael I.
    Fong, Yuman
    DeMatteo, Ronald P.
    Brennan, Murray F.
    Blumgart, Leslie H.
    Jarnagin, William R.
    [J]. ANNALS OF SURGERY, 2010, 251 (04) : 675 - 681
  • [10] Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: Correlation with anatomic site, pathologic variables, and clinical outcome
    Jarnagin, WR
    Klimstra, DS
    Hezel, M
    Gonen, M
    Fong, YM
    Roggin, K
    Cymes, K
    DeMatteo, RP
    D'Angelico, M
    Blumgart, LH
    Singh, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1152 - 1160